Eslicarbazepine and Larotrectinib interaction
Eslicarbazepine and Larotrectinib: the Larotrectinib prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Larotrectinib (VITRAKVI) label · effective 2026-05-22
Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI.
Avoid coadministration of VITRAKVI with strong CYP3A4 inducers, including St.
If coadministration of strong CYP3A4 inducers cannot be avoided, modify VITRAKVI dose as recommended.
Moderate CYP3A4 Inducers: Increase the VITRAKVI dose.
Strong and Moderate CYP3A4 Inducers Coadministration of VITRAKVI with a strong or moderate CYP3A4 inducer may decrease larotrectinib plasma concentrations, which may decrease the efficacy of VITRAKVI [see Clinical Pharmacology (12.3) ].
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.